190 related articles for article (PubMed ID: 34778040)
1. Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study.
Rokszin G; Kiss Z; Sütő G; Kempler P; Jermendy G; Fábián I; Szekanecz Z; Poór G; Wittmann I; Molnár GA
Front Oncol; 2021; 11():725465. PubMed ID: 34778040
[TBL] [Abstract][Full Text] [Related]
2. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.
Yen FS; Wei JC; Yu TS; Hung YT; Hsu CC; Hwu CM
JAMA Netw Open; 2023 Dec; 6(12):e2348431. PubMed ID: 38117497
[TBL] [Abstract][Full Text] [Related]
4. Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.
Kim M; Ha KH; Lee J; Park S; Oh KS; Bae DH; Lee JH; Kim SM; Choi WG; Hwang KK; Kim DW; Cho MC; Kim DJ; Bae JW
Korean Circ J; 2024 May; 54(5):256-267. PubMed ID: 38654455
[TBL] [Abstract][Full Text] [Related]
5. Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors.
Zerovnik S; Kos M; Locatelli I
Acta Diabetol; 2022 Feb; 59(2):233-241. PubMed ID: 34609620
[TBL] [Abstract][Full Text] [Related]
6. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
8. Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).
Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K; Sugawara M;
Diabetes Ther; 2024 Jun; 15(6):1403-1416. PubMed ID: 38653904
[TBL] [Abstract][Full Text] [Related]
9. Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis.
Ferrannini G; Lund LH; Benson L; Rizzo M; Almahmeed W; Rosano GMC; Savarese G; Cosentino F
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):10-17. PubMed ID: 35963647
[TBL] [Abstract][Full Text] [Related]
10. Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus.
Lyu YS; Oh S; Kim JH; Kim SY; Jeong MH
Cardiovasc Diabetol; 2023 Jul; 22(1):185. PubMed ID: 37481509
[TBL] [Abstract][Full Text] [Related]
11. Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.
Alkas J; Bosi A; Sjölander A; Barany P; Elinder CG; Fu EL; Carrero JJ
J Nephrol; 2023 Apr; 36(3):705-711. PubMed ID: 36459371
[TBL] [Abstract][Full Text] [Related]
12. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
[TBL] [Abstract][Full Text] [Related]
13. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).
Sugawara M; Fukuda M; Sakuma I; Wakasa Y; Funayama H; Kondo A; Itabashi N; Maruyama Y; Kamiyama T; Utsunomiya Y; Yamauchi A; Yoshii H; Yamada H; Mochizuki K;
Diabetes Ther; 2023 Sep; 14(9):1517-1535. PubMed ID: 37410308
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
16. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study.
Zerovnik S; Kos M; Locatelli I
BMJ Open; 2021 Sep; 11(9):e051549. PubMed ID: 34518273
[TBL] [Abstract][Full Text] [Related]
18. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
